What drugs target HCV NS5B polymerase and HCV NS5A protein?

3+ drugs target HCV NS5B polymerase and HCV NS5A protein, including .

What drug classes act on HCV NS5B polymerase and HCV NS5A protein?

Drug classes acting on HCV NS5B polymerase and HCV NS5A protein include Direct-acting antiviral (DAA) combination.

3 drugs 3 in Phase 3

All drugs that target HCV NS5B polymerase and HCV NS5A protein — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Sofosbuvir + Daclatasvir · Egyptian Liver Hospital · Direct-acting antiviral (DAA) combination · Virology / Hepatology
Sofosbuvir and daclatasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS5B polymerase and NS5A protein, respectively, blocking viral replication.
Sofosbuvir plus Ledipasvir · Almaza Military Fever Hospital · Direct-acting antiviral (DAA) combination · Infectious Disease / Virology
Sofosbuvir and ledipasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS5B polymerase and NS5A protein, respectively, blocking viral replication.
Sofosbuvir/Ledipasvir 24W · Iran Hepatitis Network · Direct-acting antiviral (DAA) combination · Infectious Disease / Virology
Sofosbuvir/Ledipasvir is a fixed-dose combination of a nucleotide polymerase inhibitor and a non-structural protein 5A inhibitor that blocks hepatitis C virus replication.